Navigation Links
Piramal Imaging Highlights New Data for Florbetaben F18 at AAIC 2013
Date:7/12/2013

BERLIN, BOSTON and MUMBAI, India, July 12, 2013 /PRNewswire/ -- Piramal Imaging announced today that results from five studies evaluating the Company's PET amyloid imaging agent (florbetaben F18*) will be presented at the 2013 Alzheimer's Association International Conference® (AAIC 2013) taking place in Boston, Mass. from July 13-18.

(Logo: http://photos.prnewswire.com/prnh/20130507/NE09018LOGO )

"These findings continue to reinforce the strength of the florbetaben F18 development program," said Dr. Ludger Dinkelborg, Director of the Board, Piramal Imaging SA. "We look forward to sharing the data analysis with our colleagues and the scientific community at AAIC 2013."

Florbetaben is currently being reviewed by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in the visual detection of beta-amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline.

Presentations highlighting florbetaben F18 clinical data include:

  • Midlife Vascular Risk and Late-life Amyloid Burden: Data from the Women's Healthy Ageing Project (WHAP)
    Oral Presentation: Tuesday, July 16, 2013, 4:00 p.m. – 5:30 p.m., BCEC Room 258 ABC
  • Atrophy Correction Enhances the Diagnostic Performance of Florbetaben beta-Amyloid PET Imaging
    Poster Session: Saturday, July 13, 2013, 12:30 p.m. – 2:30 p.m., BCEC Exhibit Hall A
  • PET Imaging using [18F] Florbetaben PET in Alzheimer's Disease Mouse Models
    Poster Session: Saturday, July 13, 2013, 12:30 p.m. – 2:30 p.m., BCEC Exhibit Hall A
  • Multi-center Phase 2 Trial of Florbetaben beta-Amyloid PET Imaging in Alzheimer's Disease — Results in a Close to Clinical Routine Situation
    Poster Session: Sunday, July 14, 2013, 11:45 a.m. – 2:15 p.m., BCEC Exhibit Hall A
  • 10-Year MRI changes and FBB PET: Results from the Women's Healthy Ageing Project (WHAP)
    Poster Session: Monday, July 15, 2013, 11:45 a.m. – 2:15 p.m., BCEC Exhibit Hall A

NOTE TO EDITORS: All data is embargoed until the date/time of presentation.

About Piramal Imaging SA
Piramal Imaging SA, a division of Piramal Enterprises, Ltd., was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular imaging, Piramal Imaging is focusing on a key field of modern medicine. Piramal Imaging strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life threatening diseases leading to better therapeutic outcomes and improved quality of life. For more information please go to http://imaging.piramalenterprises.com.

About Piramal Enterprises Ltd.
Piramal Enterprises is one of India's largest diversified companies, with a presence in pharmaceutical, financial services and information management sectors. Piramal Enterprises had consolidated revenues of over $650 million in FY2013. In the pharmaceutical space, PEL is one of leading custom manufacturing player globally, has presence in the global critical care segment with a portfolio of inhalation and injectable anesthetics and its OTC business is ranked no. 7 in India. PEL is also engaged in drug discovery & research and has strong pipeline of development products. In the financial services space, PEL has a real estate focused PE fund – Indiareit and a NBFC that is focused on lending to real estate and education sector. PEL's information management business, Decision Resources Group is a leading provider of information based services to the healthcare industry.

*Florbetaben is an investigational PET amyloid imaging agent currently under review by the U.S. Food and Drug Administration and the European Medicines Agency.

For media inquiries, please contact:

 

Tammy Best

Marketing Communications Manager

Piramal Enterprises – Imaging Division

Contact: +1 617-725-0070 x408

tammy.best@piramal.com

 

Akansha Pradhan

Corporate Communications

Piramal Group

Contact: +91 3351 4082

akansha.pradhan@piramal.com

 


'/>"/>
SOURCE Piramal Imaging
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013
2. IBA Molecular, Piramal Imaging Sign Agreement for New F-18 Amyloid Imaging Agent
3. Lilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents
4. Breast Imaging Technologies Market - Technology and Market Analysis & Global Forecasts to 2017
5. Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS
6. Ziehm Imaging se présente avec un site Internet français
7. Frost & Sullivan Market Share Leadership Award Highlights Acuo Technologies Accomplishments in Enterprise Imaging Informatics
8. Elbit Imaging Ltd. Announces First Quarter Results For 2013
9. Breast Cancer Imaging Market: US, EU, South America Analysis & Forecast Research Reports
10. Medical Imaging Devices - A Global Market Overview
11. Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):